Kenneth J. Hillan's most recent trade in Sangamo Therapeutics Inc was a trade of 50,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 25,000 | 99,600 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 25,000 | 74,600 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Hillan J. Kenneth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| 23andMe Holding Co Ordinary | Kenneth J. Hillan | Chief Therapeutics Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2023 | 44,381 | 237,223 | - | 0 | Class A Common Stock | |
| 23andMe Holding Co Ordinary | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.08 per share. | 05 Jun 2023 | 15,347 | 221,876 | - | 2.1 | 31,922 | Class A Common Stock |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 27,750 | 27,750 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 13,900 | 49,600 (0%) | 0% | 0 | Common Stock | |
| 23andMe Holding Co Ordinary | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.94 per share. | 20 May 2023 | 4,628 | 192,842 | - | 1.9 | 8,978 | Class A Common Stock |
| 23andMe Holding Co Ordinary | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.87 per share. | 20 Feb 2023 | 5,457 | 191,705 | - | 2.9 | 15,662 | Class A Common Stock |
| Zymeworks BC Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| 23andMe Holding Co Ordinary | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.99 per share. | 20 Nov 2022 | 4,628 | 197,162 | - | 3.0 | 13,838 | Class A Common Stock |
| 23andMe Holding Co Ordinary | Kenneth J. Hillan | Chief Therapeutics Officer | Sale of securities on an exchange or to another person at price $ 3.64 per share. | 24 Aug 2022 | 8,753 | 196,083 | - | 3.6 | 31,861 | Class A Common Stock |
| 23andMe Holding Co Ordinary | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.33 per share. | 20 Aug 2022 | 4,628 | 204,836 | - | 3.3 | 15,411 | Class A Common Stock |
| 23andMe Holding Co Ordinary | Kenneth J. Hillan | Chief Therapeutics Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.82 per share. | 01 Jun 2022 | 4,627 | 209,464 | - | 2.8 | 13,048 | Class A Common Stock |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 12,500 | 35,700 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,400 | 16,400 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,200 | 23,200 (0%) | 0% | 0 | Common Stock |